Logo Mark
Publications

Imetelstat

All Publications

IMerge: Results From a Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Imetelstat in Patients with Lower-Risk MDS

Clinical Imetelstat: MDSImetelstat
ASCO 2023

Zeidan, et al.

MYF3001: A Randomized Open Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor

Clinical Imetelstat: MFImetelstat
ASH 2022

Mascarenhas, et al.

An Open Label, Dose Escalation and Expansion, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Intermediate-1, Intermediate-2 or High-Risk Myelofibrosis

Clinical Imetelstat: MFImetelstat
ASH 2022

Bradley T, et al.

Imetelstat Achieved Prolonged, Continuous Transfusion Independence in Patients With Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory to Erythropoiesis Stimulating Agents Within the IMerge Phase 2 Study

Clinical Imetelstat: MDSImetelstat
ASH 2022

Platzbecker, et al.

Imetelstat-Mediated Alterations in Lipid Metabolism to Induce Ferroptosis As Therapeutic Strategy for Acute Myeloid Leukemia

ImetelstatNon-clinical Imetelstat
ASH 2022

Bruedigam C, et al.

Pharmacological Inhibitory Effect of Imetelstat, A Novel Human Telomerase Inhibitor in Diffuse Large B-cell Lymphoma and Peripheral T-Cell Lymphoma

ImetelstatNon-clinical Imetelstat
Blood 2022

Aradhya A, et al.

Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design

Clinical Imetelstat: MFImetelstat
Future Oncology 2022

Mascarenhas, et al.

Imetelstat Induces Leukemia Stem Cell Death in Pediatric Acute Myeloid Leukemia Patient-Derived Xenografts

ImetelstatNon-clinical Imetelstat
Journal of Clinical Medicine 2022

Barwe, et al.

Favorable overall survival with imetelstat in relapsed/refractory myelofibrosis patients compared with real-world data

Clinical Imetelstat: MFImetelstat
Annals of Hematology 2021

Kuykendall, et al.

Efficacy of Imetelstat is Independent of Molecular Subtypes in Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESA)

Clinical Imetelstat: MDSImetelstat
EHA 2021

Platzbecker, et al.

[facetwp facet="publication_load_more"]